Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1080/07391102.2020.1848634

http://scihub22266oqcxt.onion/10.1080/07391102.2020.1848634
suck pdf from google scholar
33210561!7682383!33210561
unlimited free pdf from europmc33210561    free
PDF from PMC    free
html from PMC    free
PDF vom PMID33210561  :  Publisher

suck abstract from ncbi

pmid33210561
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Structure-based identification of potential SARS-CoV-2 main protease inhibitors #MMPMID33210561
  • Khan S; Fakhar Z; Hussain A; Ahmad A; Jairajpuri DS; Alajmi MF; Hassan MI
  • J Biomol Struct Dyn 2020[Nov]; ä (ä): 1-14 PMID33210561show ga
  • To address coronavirus disease (COVID-19), currently, no effective drug or vaccine is available. In this regard, molecular modeling approaches are highly useful to discover potential inhibitors of the main protease (M(pro)) enzyme of SARS-CoV-2. Since, the M(pro) enzyme plays key roles in mediating viral replication and transcription; therefore, it is considered as an attractive drug target to control SARS-CoV-2 infection. By using structure-based drug design, pharmacophore modeling, and virtual high throughput drug screening combined with docking and all-atom molecular dynamics simulation approach, we have identified five potential inhibitors of SARS-CoV-2 M(pro). MD simulation studies revealed that compound 54035018 binds to the M(pro) with high affinity (DeltaGbind -37.40 kcal/mol), and the complex is more stable in comparison with other protein-ligand complexes. We have identified promising leads to fight COVID-19 infection as these compounds fulfill all drug-likeness properties. However, experimental and clinical validations are required for COVID-19 therapy.Communicated by Ramaswamy H. Sarma.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1 ä.ä 2020